PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Stroke. Author manuscript; available in PMC 2010 December 1.
Published in final edited form as:
PMCID: PMC2791454
NIHMSID: NIHMS161556

Caspase-1 inhibitor Prevents Neurogenic Pulmonary Edema after Subarachnoid Hemorrhage in Mice

Hidenori Suzuki, MD, PhD, Takumi Sozen, MD, Yu Hasegawa, MD, PhD, Wanqiu Chen, MS, and John H. Zhang, MD, PhD

Abstract

Background and Purpose

We examined the effects of a caspase-1 inhibitor, N-Ac-Tyr-Val-Ala-Asp-chloromethyl ketone (Ac-YVAD-CMK), on neurogenic pulmonary edema (NPE) in the endovascular perforation model of subarachnoid hemorrhage (SAH) in mice.

Methods

Ninety-seven mice were assigned to sham, SAH+vehicle, SAH+Ac-YVAD-CMK (6 or 10mg/kg) and SAH+Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK, 6mg/kg) groups. Drugs were intraperitoneally injected 1 hour post-SAH. Pulmonary edema measurements, Western blot for interleukin-1β, interleukin-18, myeloperoxidase, matrix metalloproteinase (MMP)-2, MMP-9, cleaved caspase-3 and zona occludens (ZO)-1, MMP zymography, TUNEL staining and immunostaining were performed on the lung at 24 hours post-SAH.

Results

Ten- but not 6-mg/kg of Ac-YVAD-CMK significantly inhibited a post-SAH increase in the activation of interleukin-1β and caspase-3 and the number of TUNEL-positive pulmonary endothelial cells, preventing NPE. Another antiapoptotic drug Z-VAD-FMK also reduced NPE. SAH did not change interleukin-18, myeloperoxidase, MMP-2, MMP-9, ZO-1 levels and MMP activity.

Conclusions

We report for the first time that Ac-YVAD-CMK prevents lung cell apoptosis and NPE after SAH in mice.

Keywords: apoptosis, caspase-1 inhibitor, pulmonary edema, subarachnoid hemorrhage

Neurogenic pulmonary edema (NPE) is associated with a worse clinical grade of aneurysmal subarachnoid hemorrhage (SAH).1 NPE may impair brain oxygenation, aggravate the neurogenic injury, and impede aggressive treatments for SAH and the subsequent ischemia, causing a poor outcome. However, the specific treatment for NPE has not yet been developed.

The endovascular perforation model of SAH shows a high mortality and acute metabolic changes similar to clinical findings.2 Recently, we used this model and reported that a caspase-1 inhibitor, N-Ac-Tyr-Val-Ala-Asp-chloromethyl ketone (Ac-YVAD-CMK), reduced mortality without neurological recovery at 24 hours post-SAH.2 We hypothesized that inhibitory effect of Ac-YVAD-CMK on NPE led to the reduced mortality, because some animals died with pink frothy sputum that is a sign of NPE. This study is the first to demonstrate that Ac-YVAD-CMK prevents lung cell apoptosis and NPE after SAH in mice.

Materials and Methods

All procedures were approved by Loma Linda University animal care committee.

Eighty-six CD-1 mice (35–40g, Harlan, Indianapolis, IN) were randomly assigned to sham (n=10), SAH+vehicle (n=32), SAH+Ac-YVAD-CMK (6mg/kg, n=25) and SAH+Ac-YVAD-CMK (10mg/kg, n=19) groups. SAH was produced by the endovascular perforation of the left anterior cerebral artery, and sham-operated rats underwent the identical procedures except that the suture was withdrawn without puncture.2 Ac-YVAD-CMK (Cayman Chemical, Ann Arbor, MI) was intraperitoneally injected 1 hour post-SAH.2 All evaluations were blindly performed at 24 hours post-surgery. Eighteen-point SAH grading and 21-point neurological scores (n=10, 20, 20 and 17 in the sham, SAH+vehicle, SAH+Ac-YVAD-CMK-6mg/kg, and SAH+Ac-YVAD-CMK-10mg/kg groups, respectively) were evaluated as previously described.2 The wet-to-dry weight ratio (n=6 per group) was measured on the left lung lobes,3 and MMP zymography and Western blot (n=6 per group, respectively) were performed on the right lung lobes using the rabbit anti-matrix metalloproteinase (MMP)-2 and -9 (Millipore, Temecula, CA), anti-cleaved caspase-3 (Cell Signaling, Danvers, MA), anti-interleukin (IL)-1β (Abcam, Cambridge, MA), goat anti-myeloperoxidase (MPO), anti-zona occludens (ZO)-1, anti-IL-18 and anti-ß-Actin (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies as previously described.4 Hematoxylin-eosin, TUNEL (in situ cell death detection kit; Roche, Indianapolis, IN), 4′,6-diamidino-2-phenylindole (DAPI; VECTASHIELD; Vector, Burlingame, CA) staining, and immunostaining using the rabbit anti-CD34 (Abbiotec, San Diego, CA) and goat anti-surfactant-associated protein-C (SP-C; Santa Cruz Biotechnology, Santa Cruz, CA) antibodies were performed on the lung in the sham, SAH+vehicle, and SAH+Ac-YVAD-CMK-10mg/kg groups (n=4, respectively).4

As a separate study, the effect of 10mg/kg of Ac-YVAD-CMK on blood pressure was examined via the femoral artery in 4 SAH rats. Also, 7 SAH rats received another antiapoptotic drug Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-FMK, 6mg/kg; Sigma-Aldrich, St. Louis, MO) and pulmonary edema was measured as above.

All values were expressed as mean±SD. Paired t-tests, chi-square tests and one-way analysis of variance with Scheffe correction were used as appropriate with P<0.05 considered statistically significant.

Results

Mortality

The mortality at 24 hours post-SAH was 37.5 (12 of 32 mice), 20.0 (5 of 25 mice) and 10.5 (2 of 19 mice)%, and the average survival time of dead animals was 11.5, 13.0 and 21.3 hours in the SAH+vehicle, SAH+Ac-YVAD-CMK-6mg/kg and SAH+Ac-YVAD-CMK-10mg/kg groups, respectively: the difference of mortality was significant between the vehicle and high-dose groups (P<0.05). No sham-operated mice (n=10) died.

NPE

SAH-induced brain injury was similar in terms of neurological impairment and the severity of SAH among the vehicle- and Ac-YVAD-CMK-treated groups 24 hours post-SAH (Figure 1A-B). High-dose, but not low-dose Ac-YVAD-CMK treatment significantly reduced NPE without acute changes in post-SAH blood pressure (Figure 1C-D). In the SAH+vehicle group, some alveoli were filled with fluid but only a few inflammatory cells were observed, while little or no alveolar edema was observed in the SAH+Ac-YVAD-CMK-10mg/kg group (Figure 1E). Z-VAD-FMK also showed a low mortality (14.3%, 1 of 7 rats) and significantly reduced NPE (Figure 1A-C).

Figure 1
Neurological score (A), severity of SAH (B), pulmonary edema (C) 24 hours post-SAH, changes in blood pressure within 5 hours post-SAH (D) and hematoxylin-eosin stained lungs 24 hours post-SAH (E).

Western blot and MMP zymography

High-dose Ac-YVAD-CMK significantly suppressed a post-SAH increase in pulmonary active IL-1β and caspase-3 levels (Figure 2A-B). Neither SAH nor Ac-YVAD-CMK affectedIL-18, MPO, MMP-2, MMP-9, their substrate ZO-1 levels or MMP activity (Figure 2C-I).

Figure 2
Western blot (A, active IL-1β; B, cleaved caspase-3; C, active IL-18; D, MPO; E, MMP-2; F, MMP-9; G, ZO-1) and MMP zymography (H, MMP-2; I, MMP-9) in the right pulmonary lobes 24 hours post-SAH. N=6 per group.

Histological assessment

SAH significantly increased the number of TUNEL-positive pulmonary endothelial cells, which were significantly inhibited by the high-dose Ac-YVAD-CMK treatment (Figure 3).

Figure 3
Combined TUNEL/DAPI staining (A), TUNEL/endothelial cell (CD34)/type 2 alveolar epithelial cell (SP-C) immunostaining (B), and TUNEL-positive cell (arrows) counting (C) in the lungs 24 hours post-SAH.

Discussion

Increased hydrostatic pressure in the pulmonary capillaries by an excessive release of catecholamines has been presumed to be the main pathogenetic factor for the development of NPE.1,5 The hydrostatic pressure-independent mechanism has been also suggested but remains unknown. Norepinephrine not only leads to a hydrostatic pulmonary edema, but also causes an activation of cytokines.5 Inflammatory reactions can cause pulmonary edema associated with recruitment of neutrophils, which release MMPs that damage the alveolar-capillary barrier.3 However, inflammation is considered not to develop NPE but potentially to maintain and aggravate the edema by increasing capillary permeability.5 Although norepinephrine also causes lung cell apoptosis, resulting in pulmonary edema,6 the possibility that apoptosis is involved in the pathogenesis of NPE has not been investigated.

Caspase-1 inhibitors prevent the release of active IL-1β and IL-18, which initiate inflammation, resulting in decreased pulmonary edema.7 Ac-YVAD-CMK also prevents apoptosis independent of its caspase-1 inhibitor activity, in addition to an indirect decrease in apoptosis through the inflammatory cascade modulation.8

This study showed that pulmonary endothelial cell apoptosis, but not neutrophil infiltration and MMP activation, contributes to the pathophysiology of post-SAH NPE. Ac-YVAD-CMK suppressed post-SAH IL-1β activation and inhibited apoptosis, preventing NPE. The effects of another antiapoptotic drug Z-VAD-FMK supported the involvement of apoptosis in the development of NPE. The alveolar-capillary barrier weakened by apoptosis would cause diminished capacity to withstand hydrostatic pressure, resulting in NPE.

This study has some limitations including no studies of the time course of plasma norepinephrine concentration, pulmonary hypertension, lung cell apoptosis and NPE, and the relationship between the intracranial pressure and NPE, as well as the effects of AC-YVAD-CMK on norepinephrine levels and pulmonary hypertension. Thus, further studies are needed.

Acknowledgements and Funding

This study was partially supported by grants (NS053407) from the National Institutes of Health to J.H.Z.

Footnotes

The authors report no conflicts of interest.

References

1. Baumann A, Audibert G, Mcdonnel J, Mertes PM. Neurogenic pulmonary edema. Acta Anaesthesiol Scand. 2007;51:447–455. [PubMed]
2. Sozen T, Tsuchiyama R, Hasegawa Y, Suzuki H, Jadhav V, Nishizawa S, Zhang JH. Role of interleukin-1β in early brain injury after subarachnoid hemorrhage in mice. Stroke. 2009;40:2519–2525. [PMC free article] [PubMed]
3. Steinberg J, Halter J, Schiller H, Gatto L, Carney D, Lee H-M, Golub L, Nieman G. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock. 2005;24:348–356. [PubMed]
4. Yatsushige H, Ostrowski RP, Tsubokawa T, Colohan A, Zhang JH. Role of c-Jun N-terminal kinase in early brain injury after subarachnoid hemorrhage. J Neurosci Res. 2007;85:1436–1448. [PubMed]
5. Raßler B, Reißig C, Briest W, Tannapfel A, Zimmer H-G. Pulmonary edema and pleural effusion in norepinephrine-stimulated rats: hemodynamic or inflammatory effect? Mol Cell Biochem. 2003;250:55–63. [PubMed]
6. Uhal BD, Rayford H, Zhuang J, Li X, Laukka J, Soledad-Conrad V. Apoptosis-dependent acute lung injury and repair after intratracheal instillation of noradrenaline in rats. Exp Physiol. 2003;88:269–275. [PubMed]
7. Zhang X-H, Zhu R-M, Xu W-A, Wan H-J, Lu H. Therapeutic effects of caspase-1 inhibitors on acute lung injury in experimental severe acute pancreatitis. World J Gastroenterol. 2007;13:623–627. [PubMed]
8. Zhang Y, Rosenberg PA. Caspase-1 and poly (ADP-ribose) polymerase inhibitors may protect against peroxynitrite-induced neurotoxicity independent of their enzyme inhibitor activity. Eur J Neurosci. 2004;20:1727–1736. [PubMed]